Cargando…

Real-World Evidence of Safety and Efficacy of Carboplatin plus Nanoparticle Albumin-Bound Paclitaxel in Patients with Advanced Non-Small-Cell Lung Cancer and Preexisting Interstitial Lung Disease: A Retrospective Study

BACKGROUND: Standard chemotherapy for advanced non-small-cell lung cancer (NSCLC) with preexisting interstitial lung disease (ILD) has not yet been established. Although a combination of carboplatin and paclitaxel is most frequently used for patients with advanced NSCLC and ILD, the safety and effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Araya, Tomoyuki, Kita, Toshiyuki, Ueda, Tsukasa, Terada, Nanao, Sakai, Tamami, Yamamura, Kenta, Kurokawa, Koji, Uchida, Yuka, Sone, Takashi, Kimura, Hideharu, Kasahara, Kazuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446117/
https://www.ncbi.nlm.nih.gov/pubmed/31015884
http://dx.doi.org/10.1155/2019/5315903
_version_ 1783408302333362176
author Araya, Tomoyuki
Kita, Toshiyuki
Ueda, Tsukasa
Terada, Nanao
Sakai, Tamami
Yamamura, Kenta
Kurokawa, Koji
Uchida, Yuka
Sone, Takashi
Kimura, Hideharu
Kasahara, Kazuo
author_facet Araya, Tomoyuki
Kita, Toshiyuki
Ueda, Tsukasa
Terada, Nanao
Sakai, Tamami
Yamamura, Kenta
Kurokawa, Koji
Uchida, Yuka
Sone, Takashi
Kimura, Hideharu
Kasahara, Kazuo
author_sort Araya, Tomoyuki
collection PubMed
description BACKGROUND: Standard chemotherapy for advanced non-small-cell lung cancer (NSCLC) with preexisting interstitial lung disease (ILD) has not yet been established. Although a combination of carboplatin and paclitaxel is most frequently used for patients with advanced NSCLC and ILD, the safety and efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel (nab-paclitaxel) are yet to be elucidated. OBJECTIVES: This study aimed to evaluate the safety and efficacy of carboplatin plus nab-paclitaxel for advanced NSCLC with ILD. METHODS: This retrospective study included nine patients with advanced NSCLC and ILD who received carboplatin plus nab-paclitaxel as first-line chemotherapy at the National Hospital Organization Kanazawa Medical Center between April 2013 and December 2017. The ILD-GAP index was used to evaluate mortality risk of baseline ILD. RESULTS: A usual interstitial pneumonia (UIP) pattern of ILD was observed in five (55.6%) patients on their baseline high-resolution computed tomography (HRCT) scans. The median ILD-GAP index was 4 (range, 1–5), and six (66.7%) patients had ILD-GAP index ≥4. We observed no ILD exacerbations or chemotherapy-related deaths. The overall response and disease control rates were 77.8% (95% CI, 40.0–97.2) and 88.9% (95% CI, 51.8–97.2), respectively. The median progression-free survival and overall survival were 5.8 months (95% CI, 2.1–7.7) and 8.0 months (95% CI, 2.6–16.8), respectively. CONCLUSIONS: Carboplatin plus nab-paclitaxel showed favorable safety and efficacy in patients who had advanced NSCLC and ILD with a high risk of mortality. Prospective studies are required to further confirm these results.
format Online
Article
Text
id pubmed-6446117
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-64461172019-04-23 Real-World Evidence of Safety and Efficacy of Carboplatin plus Nanoparticle Albumin-Bound Paclitaxel in Patients with Advanced Non-Small-Cell Lung Cancer and Preexisting Interstitial Lung Disease: A Retrospective Study Araya, Tomoyuki Kita, Toshiyuki Ueda, Tsukasa Terada, Nanao Sakai, Tamami Yamamura, Kenta Kurokawa, Koji Uchida, Yuka Sone, Takashi Kimura, Hideharu Kasahara, Kazuo Can Respir J Clinical Study BACKGROUND: Standard chemotherapy for advanced non-small-cell lung cancer (NSCLC) with preexisting interstitial lung disease (ILD) has not yet been established. Although a combination of carboplatin and paclitaxel is most frequently used for patients with advanced NSCLC and ILD, the safety and efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel (nab-paclitaxel) are yet to be elucidated. OBJECTIVES: This study aimed to evaluate the safety and efficacy of carboplatin plus nab-paclitaxel for advanced NSCLC with ILD. METHODS: This retrospective study included nine patients with advanced NSCLC and ILD who received carboplatin plus nab-paclitaxel as first-line chemotherapy at the National Hospital Organization Kanazawa Medical Center between April 2013 and December 2017. The ILD-GAP index was used to evaluate mortality risk of baseline ILD. RESULTS: A usual interstitial pneumonia (UIP) pattern of ILD was observed in five (55.6%) patients on their baseline high-resolution computed tomography (HRCT) scans. The median ILD-GAP index was 4 (range, 1–5), and six (66.7%) patients had ILD-GAP index ≥4. We observed no ILD exacerbations or chemotherapy-related deaths. The overall response and disease control rates were 77.8% (95% CI, 40.0–97.2) and 88.9% (95% CI, 51.8–97.2), respectively. The median progression-free survival and overall survival were 5.8 months (95% CI, 2.1–7.7) and 8.0 months (95% CI, 2.6–16.8), respectively. CONCLUSIONS: Carboplatin plus nab-paclitaxel showed favorable safety and efficacy in patients who had advanced NSCLC and ILD with a high risk of mortality. Prospective studies are required to further confirm these results. Hindawi 2019-03-20 /pmc/articles/PMC6446117/ /pubmed/31015884 http://dx.doi.org/10.1155/2019/5315903 Text en Copyright © 2019 Tomoyuki Araya et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Araya, Tomoyuki
Kita, Toshiyuki
Ueda, Tsukasa
Terada, Nanao
Sakai, Tamami
Yamamura, Kenta
Kurokawa, Koji
Uchida, Yuka
Sone, Takashi
Kimura, Hideharu
Kasahara, Kazuo
Real-World Evidence of Safety and Efficacy of Carboplatin plus Nanoparticle Albumin-Bound Paclitaxel in Patients with Advanced Non-Small-Cell Lung Cancer and Preexisting Interstitial Lung Disease: A Retrospective Study
title Real-World Evidence of Safety and Efficacy of Carboplatin plus Nanoparticle Albumin-Bound Paclitaxel in Patients with Advanced Non-Small-Cell Lung Cancer and Preexisting Interstitial Lung Disease: A Retrospective Study
title_full Real-World Evidence of Safety and Efficacy of Carboplatin plus Nanoparticle Albumin-Bound Paclitaxel in Patients with Advanced Non-Small-Cell Lung Cancer and Preexisting Interstitial Lung Disease: A Retrospective Study
title_fullStr Real-World Evidence of Safety and Efficacy of Carboplatin plus Nanoparticle Albumin-Bound Paclitaxel in Patients with Advanced Non-Small-Cell Lung Cancer and Preexisting Interstitial Lung Disease: A Retrospective Study
title_full_unstemmed Real-World Evidence of Safety and Efficacy of Carboplatin plus Nanoparticle Albumin-Bound Paclitaxel in Patients with Advanced Non-Small-Cell Lung Cancer and Preexisting Interstitial Lung Disease: A Retrospective Study
title_short Real-World Evidence of Safety and Efficacy of Carboplatin plus Nanoparticle Albumin-Bound Paclitaxel in Patients with Advanced Non-Small-Cell Lung Cancer and Preexisting Interstitial Lung Disease: A Retrospective Study
title_sort real-world evidence of safety and efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel in patients with advanced non-small-cell lung cancer and preexisting interstitial lung disease: a retrospective study
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446117/
https://www.ncbi.nlm.nih.gov/pubmed/31015884
http://dx.doi.org/10.1155/2019/5315903
work_keys_str_mv AT arayatomoyuki realworldevidenceofsafetyandefficacyofcarboplatinplusnanoparticlealbuminboundpaclitaxelinpatientswithadvancednonsmallcelllungcancerandpreexistinginterstitiallungdiseasearetrospectivestudy
AT kitatoshiyuki realworldevidenceofsafetyandefficacyofcarboplatinplusnanoparticlealbuminboundpaclitaxelinpatientswithadvancednonsmallcelllungcancerandpreexistinginterstitiallungdiseasearetrospectivestudy
AT uedatsukasa realworldevidenceofsafetyandefficacyofcarboplatinplusnanoparticlealbuminboundpaclitaxelinpatientswithadvancednonsmallcelllungcancerandpreexistinginterstitiallungdiseasearetrospectivestudy
AT teradananao realworldevidenceofsafetyandefficacyofcarboplatinplusnanoparticlealbuminboundpaclitaxelinpatientswithadvancednonsmallcelllungcancerandpreexistinginterstitiallungdiseasearetrospectivestudy
AT sakaitamami realworldevidenceofsafetyandefficacyofcarboplatinplusnanoparticlealbuminboundpaclitaxelinpatientswithadvancednonsmallcelllungcancerandpreexistinginterstitiallungdiseasearetrospectivestudy
AT yamamurakenta realworldevidenceofsafetyandefficacyofcarboplatinplusnanoparticlealbuminboundpaclitaxelinpatientswithadvancednonsmallcelllungcancerandpreexistinginterstitiallungdiseasearetrospectivestudy
AT kurokawakoji realworldevidenceofsafetyandefficacyofcarboplatinplusnanoparticlealbuminboundpaclitaxelinpatientswithadvancednonsmallcelllungcancerandpreexistinginterstitiallungdiseasearetrospectivestudy
AT uchidayuka realworldevidenceofsafetyandefficacyofcarboplatinplusnanoparticlealbuminboundpaclitaxelinpatientswithadvancednonsmallcelllungcancerandpreexistinginterstitiallungdiseasearetrospectivestudy
AT sonetakashi realworldevidenceofsafetyandefficacyofcarboplatinplusnanoparticlealbuminboundpaclitaxelinpatientswithadvancednonsmallcelllungcancerandpreexistinginterstitiallungdiseasearetrospectivestudy
AT kimurahideharu realworldevidenceofsafetyandefficacyofcarboplatinplusnanoparticlealbuminboundpaclitaxelinpatientswithadvancednonsmallcelllungcancerandpreexistinginterstitiallungdiseasearetrospectivestudy
AT kasaharakazuo realworldevidenceofsafetyandefficacyofcarboplatinplusnanoparticlealbuminboundpaclitaxelinpatientswithadvancednonsmallcelllungcancerandpreexistinginterstitiallungdiseasearetrospectivestudy